Actavis PLC (ACT)

ACT on New York Consolidated

265.39USD
19 Dec 2014
Price Change (% chg)

$1.64 (+0.62%)
Prev Close
$263.75
Open
$263.75
Day's High
$267.61
Day's Low
$261.79
Volume
3,528,571
Avg. Vol
3,102,057
52-wk High
$272.75
52-wk Low
$161.92

ACT

Chart for ACT

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.31
Market Cap (Mil.): $70,344.57
Shares Outstanding (Mil.): 265.06
Dividend: --
Yield (%): --

Financials

  ACT Industry Sector
P/E (TTM): -- 37.39 38.03
EPS (TTM): -4.18 -- --
ROI: -3.50 19.00 18.26
ROE: -6.36 19.79 19.16
Search Stocks

Spain's Almirall gains on report of Actavis interest

Dec 19 - Shares in Spanish drugmaker Almirall jumped 9 percent on Friday after a Bloomberg report of potential takeover interest from Actavis.

19 Dec 2014

UPDATE 1-U.S. judge says Actavis must keep selling Alzheimer drug

Dec 11 - A U.S. judge said in a preliminary injunction on Thursday that Actavis Plc must continue to sell its Alzheimer's drug after a lawsuit alleged the company was trying to limit generic competition while it launched an extended-release version of the widely used medicine.

11 Dec 2014

U.S. judge rules Actavis must continue to sell Alzheimer's drug

- A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

11 Dec 2014

U.S. judge rules Actavis must continue to sell Alzheimer's drug

- A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

11 Dec 2014

U.S. judge rules Actavis must continue to sell Alzheimer's drug

Dec 11 - A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

11 Dec 2014

FDA panel recommends approval for Actavis' antibiotic drug

- Actavis Plc said a panel advising the United States Food and Drug Administration recommended the approval of its antibiotic to treat two infections caused by drug-resistant bacteria.

05 Dec 2014

FDA panel recommends approval for Actavis' antibiotic drug

Dec 5 - Actavis Plc said a panel advising the United States Food and Drug Administration recommended the approval of its antibiotic to treat two infections caused by drug-resistant bacteria.

05 Dec 2014

Ackman's Pershing Square still holds 26.6 million Allergan shares

BOSTON, Nov 26 - Hedge fund manager William Ackman told investors in a letter that his firm still owns 26.6 million shares in Allergan Inc. which were valued at $5.6 billion one week after the Botox maker agreed to sell itself to rival pharmaceutical company Actavis Plc.

26 Nov 2014

Actavis mulls job cuts, China expansion: Bloomberg

- Generic drugmaker Actavis Plc is planning to cut employees and expand in China, a Bloomberg report said citing an interview by Chief Executive Officer Brent Saunders on Bloomberg Television.

24 Nov 2014

Actavis mulls job cuts, China expansion - Bloomberg

Nov 24 - Generic drugmaker Actavis Plc is planning to cut employees and expand in China, a Bloomberg report said citing an interview by Chief Executive Officer Brent Saunders on Bloomberg Television.

24 Nov 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks